Patents by Inventor Shigekazu Sasaki
Shigekazu Sasaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230295628Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.Type: ApplicationFiled: February 2, 2023Publication date: September 21, 2023Applicants: National University Corporation Tokyo Medical and Dental University, Takeda Pharmaceutical Company LimitedInventors: Takanori Yokota, Tetsuya Nagata, Hideki Furukawa, Yasuo Nakagawa, Takatoshi Yogo, Ryosuke Tokunoh, Shigekazu Sasaki, Kosuke Hidaka, Tomohiro Seki, Kenichi Miyata, Akio Uchida
-
Patent number: 11597928Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.Type: GrantFiled: March 13, 2019Date of Patent: March 7, 2023Assignees: National University Corporation Tokyo Medical and Dental University, Takeda Pharmaceutical Company LimitedInventors: Takanori Yokota, Tetsuya Nagata, Hideki Furukawa, Yasuo Nakagawa, Takatoshi Yogo, Ryosuke Tokunoh, Shigekazu Sasaki, Kosuke Hidaka, Tomohiro Seki, Kenichi Miyata, Akio Uchida
-
Publication number: 20220370491Abstract: The object of the present invention is to provide a nucleic acid agent that is efficiently delivered to the nervous system, for example, the central nervous system to which drug delivery can be prevented by BBB, and produces an antisense effect on the target transcriptional product at the delivery site, and a composition comprising the same. In an embodiment, the present invention provides a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand that hybridizes to a part of a target transcriptional product and has an antisense effect on the target transcriptional product, and a second nucleic acid strand that comprises a base sequence complementary to the first nucleic acid strand and is bound to a C22-35 alkyl group optionally substituted with a hydroxy group or an analog thereof.Type: ApplicationFiled: September 16, 2020Publication date: November 24, 2022Applicants: National University Corporation Tokyo Medical and Dental University, Takeda Pharmaceutical Company LimitedInventors: Takanori Yokota, Testuya Nagata, Hideki Furukawa, Takatoshi Yogo, Yasuo Nakagawa, Shigekazu Sasaki, Ryosuke Tokunoh, Tomohiro Seki, Kosuke Hidaka, Fumiaki Kikuchi, Osamu Kubo, Takahito Kasahara, Takuto Kojima, Junsi Wang, Norihito Tokunaga
-
Publication number: 20210340114Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: ApplicationFiled: April 9, 2021Publication date: November 4, 2021Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
-
Publication number: 20210163934Abstract: The object of the present invention is to provide a nucleic acid agent that can be efficiently delivered to the nervous system, particularly the central nervous system to which the BBB mechanism prevents drug delivery, and can produce an antisense effect on a target transcriptional product at the delivered site, and a composition comprising the same. Provided is a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand capable of hybridizing to part of a target transcriptional product, and has an antisense effect on the target transcriptional product, to a second nucleic acid strand comprising a base sequence complementary to the first nucleic acid strand, and is bound to tocopherol or an analog thereof, cholesterol or an analog thereof, or a substituted or unsubstituted C1-30 alkyl group, a substituted or unsubstituted C2-30 alkenyl group, or a substituted or unsubstituted C1-30 alkoxy group.Type: ApplicationFiled: March 22, 2019Publication date: June 3, 2021Applicant: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITYInventors: Takanori YOKOTA, Tetsuya NAGATA, Hideki FURUKAWA, Yasuo NAKAGAWA, Takatoshi YOGO, Ryosuke TOKUNOH, Shigekazu SASAKI, Kosuke HIDAKA, Tomohiro SEKI, Kenichi MIYATA, Yusuke ADACHI, Naoto ARIMURA
-
Patent number: 10975043Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: GrantFiled: January 27, 2020Date of Patent: April 13, 2021Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
-
Publication number: 20210024929Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.Type: ApplicationFiled: March 13, 2019Publication date: January 28, 2021Applicants: National University Corporation Tokyo Medical and Dental University, Takeda Pharmaceutical Company LimitedInventors: Takanori Yokota, Tetsuya Nagata, Hideki Furukawa, Yasuo Nakagawa, Takatoshi Yogo, Ryosuke Tokunoh, Shigekazu Sasaki, Kosuke Hidaka, Tomohiro Seki, Kenichi Miyata, Akio Uchida
-
Publication number: 20200163970Abstract: Provided is a novel compound or salt thereof that induces degradation by autophagy of an intracellular molecule. In this compound, a ligand having activity to bind to an intracellular molecule and a structure having activity to induce autophagy of an intracellular molecule are linked via a linker without loss of the activity of the ligand and the structure.Type: ApplicationFiled: February 2, 2018Publication date: May 28, 2020Inventors: Hirokazu ARIMOTO, Kaori ITTO, Daiki TAKAHASHI, Nobuo CHO, Hiroshi NARA, Kenichiro SHIMOKAWA, Taiichi OHRA, Shigekazu SASAKI, Naoki ISHII
-
Patent number: 10544111Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: GrantFiled: December 21, 2018Date of Patent: January 28, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
-
Publication number: 20190119225Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: ApplicationFiled: December 21, 2018Publication date: April 25, 2019Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
-
Patent number: 10214498Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: GrantFiled: October 22, 2015Date of Patent: February 26, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
-
Publication number: 20180237404Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: ApplicationFiled: October 22, 2015Publication date: August 23, 2018Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro BANNO, Masahiro KAMAURA, Kazuaki TAKAMI, Koichiro FUKUDA, Shigekazu SASAKI
-
Patent number: 10017508Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.Type: GrantFiled: September 13, 2016Date of Patent: July 10, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Satoshi Mikami, Shinji Nakamura, Tomoko Ashizawa, Shigekazu Sasaki, Takahiko Taniguchi, Izumi Nomura, Masanori Kawasaki
-
Publication number: 20180139981Abstract: The present invention relates to a sliced chocolate that has high film releasability and favorable breakage resistance, and still maintains original tastes of nama-chocolate, and to a method for manufacturing the same. More specifically, the sliced chocolate of the invention includes gelatin, in which the sliced chocolate has a gelatin content of from 0.8 to 9% by mass with respect to the sliced chocolate, and is an oil-in-water type emulsion.Type: ApplicationFiled: May 19, 2016Publication date: May 24, 2018Applicant: BOURBON CORPORATIONInventors: Shigekazu SASAKI, Mutsumi NAKAMURA, Kuniaki KATSUMATA
-
Patent number: 9975903Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].Type: GrantFiled: December 24, 2015Date of Patent: May 22, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Minoru Sasaki, Fumiaki Kikuchi, Zenichi Ikeda, Keiko Kakegawa, Yoichi Nishikawa, Shigekazu Sasaki, Koichiro Fukuda, Kazuaki Takami, Yoshihiro Banno, Masahiro Kamaura
-
Patent number: 9944596Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: GrantFiled: October 22, 2015Date of Patent: April 17, 2018Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Banno, Masahiro Kamaura, Takahiko Taniguchi, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
-
Publication number: 20170349605Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].Type: ApplicationFiled: December 24, 2015Publication date: December 7, 2017Applicant: Takeda Pharmaceutical Company LimitedInventors: Minoru SASAKI, Fumiaki KIKUCHI, Zenichi IKEDA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Shigekazu SASAKI, Koichiro FUKUDA, Kazuaki TAKAMI, Yoshihiro BANNO, Masahiro KAMAURA
-
Publication number: 20170233339Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: ApplicationFiled: October 22, 2015Publication date: August 17, 2017Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro BANNO, Masahiro KAMAURA, Takahiko TANIGUCHI, Kazuaki TAKAMI, Koichiro FUKUDA, Shigekazu SASAKI
-
Publication number: 20170129887Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.Type: ApplicationFiled: September 13, 2016Publication date: May 11, 2017Inventors: Satoshi MIKAMI, Shinji NAKAMURA, Tomoko ASHIZAWA, Shigekazu SASAKI, Takahiko TANIGUCHI, Izumi NOMURA, Masanori KAWASAKI
-
Patent number: 9556200Abstract: The present invention provides a compound having a superior serotonin 5-HT2C receptor activating action. The present invention relates to a compound represented by the formula (1) wherein ring A is an aromatic carbocycle optionally having substituent(s) or an aromatic heterocycle optionally having substituent(s), X is —N(R1)—, —O— or the like, when ring A is an aromatic carbocycle optionally having substituent(s), then R1 is a hydrogen atom, an alkyl group optionally having substituent(s), or the like, and when ring A is an aromatic heterocycle optionally having substituent(s), then R1 is a hydrogen atom, an alkyl group optionally having substituent(s), a cycloalkyl group optionally having substituent(s), or the like, is a single bond or a double bond, and n is an integer of 0, 1 or 2, or a salt thereof.Type: GrantFiled: March 6, 2013Date of Patent: January 31, 2017Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Tomokazu Kusumoto, Shigekazu Sasaki, Hironobu Maezaki